Quote:

---

Plus there is no data for NASH or cancer yet

---

*No human data for NASH and only one patient results for cancer so far. There is plenty of NASH and cancer data, just not fully proven in clinical trials yet.

So does this mean that no valuation should be assigned to pre-clinical data? first patient cancer results? safety profile of leronlimab? Heck even combo or mono HIV that has been proven in over 800 people so far?

I think CI is correct in why we are at ~$.30....OTC, continued raises to get cash in the CYDY account.....not because the science is in question.